Remnant Cholesterol

When Remnant Cholesterol is HIGH

Elevated remnant cholesterol reflects excess circulating triglyceride-rich lipoprotein remnants that accumulate when VLDL clearance is impaired or hepatic VLDL production is excessive. These particles are directly atherogenic: unlike mature VLDL (which is too large to penetrate the arterial wall), VLDL remnants and IDL are small enough to infiltrate the subendothelial space and deposit cholesterol in plaques. Mendelian randomisation studies by Varbo et al. (2013) demonstrated that each 1 mmol/L increase in remnant cholesterol is associated with a 2.8-fold increased risk of ischaemic heart disease, independent of LDL.

The key drivers of elevated remnant cholesterol are insulin resistance (impairs lipoprotein lipase activity needed for VLDL clearance), high refined carbohydrate intake (stimulates hepatic de novo lipogenesis and VLDL secretion), and genetic conditions such as familial combined hyperlipidaemia or familial dysbetalipoproteinaemia (Type III). When remnant cholesterol is above 0.8 mmol/L, triglycerides are usually also elevated, confirming the VLDL overproduction pattern.

Management steps:

• Omega-3 (EPA/DHA) -- 3-4g/day: directly reduces hepatic VLDL secretion and accelerates VLDL particle clearance, lowering remnant cholesterol by 20-30%
• Berberine -- 500mg 2-3x/day: activates hepatic AMPK, suppressing fatty acid synthesis and reducing VLDL production
• Fibrates (Fenofibrate) -- if remnant cholesterol is persistently above 1.0 mmol/L: activates PPAR-alpha, accelerating VLDL catabolism. Prescription required
• Reduce refined carbohydrates and sugar: the primary dietary driver of VLDL overproduction
• Lose excess body fat if present: visceral fat drives hepatic VLDL secretion via increased free fatty acid flux to the liver
• Regular aerobic exercise: increases lipoprotein lipase activity and improves VLDL clearance

PED-Specific Considerations: GH use at supraphysiological doses substantially increases hepatic VLDL secretion, elevating remnant cholesterol as a downstream consequence. This is dose-dependent and partly explains why high-dose GH users develop worsening triglycerides and remnant particles even with otherwise good diets. MK-677 produces a similar but more modest effect. AAS, particularly oral 17-alpha-alkylated compounds, impair hepatic VLDL receptor activity and lipoprotein lipase expression, slowing remnant clearance. Monitoring remnant cholesterol is particularly valuable in users running GH plus AAS combinations, where both VLDL overproduction and impaired clearance compound each other.

When Remnant Cholesterol is LOW

Low remnant cholesterol (below 0.5 mmol/L) is the optimal and desirable finding. It indicates efficient VLDL metabolism, good insulin sensitivity, and a low-risk lipoprotein profile. No intervention is required.

PED-Specific Considerations: TRT at physiological replacement doses has minimal impact on remnant cholesterol provided insulin sensitivity is maintained. Nandrolone and boldenone show lesser VLDL effects than oral compounds. A low remnant cholesterol during a cycle indicates that hepatic lipoprotein metabolism is relatively intact despite AAS exposure.

References:

• Varbo, A., Benn, M., Tybjaerg-Hansen, A., Jorgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013). Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American College of Cardiology, 61(4), 427-436. DOI: 10.1016/j.jacc.2012.08.1026
• Nordestgaard, B. G., & Varbo, A. (2014). Triglycerides and cardiovascular disease. The Lancet, 384(9943), 626-635. DOI: 10.1016/S0140-6736(14)61177-6
• Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions, 45(5), 1105-1115. DOI: 10.1042/BST20160474
• Dong, H., Zhao, Y., Zhao, L., & Lu, F. (2013). The effects of berberine on blood lipids: A systemic review and meta-analysis. Planta Medica, 79(6), 437-446. DOI: 10.1055/s-0032-1328321